

Amendment to the Claims:

This listing of claims will replace all previous versions, and listings, of claims in this application.

Listing of Claims:

Claim 1. (Currently amended) A pharmaceutical composition comprising a positive modulator of a nicotinic receptor agonist wherein said positive modulator is 5-hydroxyindole together with a pharmaceutically acceptable carrier, said positive modulator having the capability to increase the efficacy of the said nicotinic receptor agonist.

Claim 2. (Original) The pharmaceutical composition according to claim 1, in addition comprising a nicotinic receptor agonist.

Claims 3 - 30 (Cancelled).

Claim 31. (Previously presented) The pharmaceutical composition according to claim 1, wherein the said nicotinic receptor agonist is an $\alpha 7$ -nicotinic receptor agonist.

Claim 32. (Previously presented) The pharmaceutical composition according to claim 2, wherein the said nicotinic receptor agonist is an $\alpha 7$ -nicotinic receptor agonist.

Claim 33. (Cancelled).

Claim 34. (Previously presented) A method for the treatment of a condition associated with reduced nicotine transmission, by administering to a patient in need of such treatment, a medically effective amount of a positive modulator of a nicotinic receptor agonist, wherein said positive modulator is 5-hydroxyindole, said positive modulator having the capability to increase the efficacy of the said nicotinic receptor agonist.

Claim 35. (Previously presented) The method according to claim 34, wherein the said positive modulator is administered together with a nicotinic receptor agonist.

Claims 36 - 37. (Cancelled).

Claim 38. (Previously presented) The method according to claim 34, wherein the said nicotinic receptor agonist is an $\alpha 7$ -nicotinic receptor agonist.

Claim 39. (Previously presented) The method according to claim 35, wherein the said nicotinic receptor agonist is an $\alpha 7$ -nicotinic receptor agonist.

Claim 40. (Cancelled).

Claim 41. (Previously presented) The method according to claim 34, for the treatment of Alzheimer's disease, Attention Deficit Hyperactivity Disorder, schizophrenia, anxiety or nicotine addiction.

Claim 42. (Previously presented) The method according to claim 35, for the treatment of Alzheimer's disease, Attention Deficit Hyperactivity Disorder, schizophrenia, anxiety or nicotine addiction.

Claim 43. (Cancelled).

Claim 44. (Previously presented) The method according to claim 38, for the treatment of Alzheimer's disease, Attention Deficit Hyperactivity Disorder, schizophrenia, anxiety or nicotine addiction.

Claim 45. (Previously presented) The method according to claim 34 for the treatment of Alzheimer's disease.

Claim 46. (Previously presented) The method according to claim 35 for the treatment of Alzheimer's disease.

Claim 47. (Cancelled).

Claim 48. (Previously presented) The method according to claim 38 for the treatment of Alzheimer's disease.

Claim 49. (Previously presented) The method according to claim 34 for the treatment of Attention Deficit Hyperactivity Disorder.

Claim 50. (Previously presented) The method according to claim 35 for the treatment of Attention Deficit Hyperactivity Disorder.

Claim 51. (Cancelled).

Claim 52. (Previously presented) The method according to claim 38 for the treatment of Attention Deficit Hyperactivity Disorder.

Claim 53. (Previously presented) The method according to claim 34 for the treatment of schizophrenia.

Claim 54. (Previously presented) The method according to claim 35 for the treatment of schizophrenia.

Claim 55. (Cancelled).

Claim 56. (Previously presented) The method according to claim 38 for the treatment of schizophrenia.

Claim 57. (Previously presented) The method according to claim 34 for the treatment of nicotine addiction.

Claim 58. (Previously presented) The method according to claim 35 for the treatment of nicotine addiction.

Claim 59. (Cancelled).

Claim 60. (Previously presented) The method according to claim 38 for the treatment of nicotine addiction.